Biography
Biography: Rolando Toyos
Abstract
Introduction: This project was undertaken to assess the clinical value of using a new transscleral cyclophotocoagulation device in patients with mild to severe glaucoma including those who have unsuccessfully undergone other procedures. This is a one year update of earlier reported data.
Method: This is a single site review of 26 eyes of 20 patients, 4 eyes were classified as mild glaucoma, 5 as moderate and 18 as severe or end stage glaucoma. Two eyes of one patient were lost to follow up. All eyes but 3 had previously undergone phacoemulsification and SLT or MLT. 4 eyes had previously undergone trabeculectomy.
Results: Patients undergoing the procedure had an average IOP of 25.6 and were on an average of 3 IOP lowering meds. After the procedure, patients were started on difluprednate hourly for the first day then tapered over 3 weeks. Average IOP drop at POD 1 was 20% and 34% at pod7 (using an average 1.3 IOP lowering meds). At POD14, average IOP from baseline was 8% using one IOP lowering medication. At one month, IOP was down by 20% and average number of IOP reducing medications was 1.2. At 6-12 months, the average IOP lowering was 30% compared with baseline IOP on and average of 1.8 medications. There were no serious adverse events.
Conclusion: Patients with glaucoma of varying severities are able to safely undergo transscleral cyclophotocoagulation. On average, IOPs were reduced by 30% over one years’ time and number of IOP lowering medications was reduced by 60%. Further study is required to determine ideal treatment guidelines.